FDA approves Eli Lilly's GLP-1 pill, opening the next phase of the weight loss drug market

CNBC·Apr 1

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

The FDA has approved a weight loss pill from Eli Lilly, a GLP-1 medication that can be taken without food or water restrictions. This approval is seen as a development in the weight loss drug market and may impact the market share of other companies, such as Novo Nordisk. The pill, known as Foundayo, provides another option for patients seeking treatment for obesity.

Full coverage

FDA approves Eli Lilly’s weight-loss pill; Judge revokes citizenship over stolen medical secrets for China; new COVID-19 ‘Cicada’ variant spreads to 25 states – Morning Medical Update

Medical Economics·1d ago

FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions

Eli Lilly and Company·Apr 1

Fetching the latest headlines…

FDA approves Eli Lilly's GLP-1 pill, opening the next phase of the weight loss drug market

Full coverage

FDA approves Eli Lilly’s weight-loss pill; Judge revokes citizenship over stolen medical secrets for China; new COVID-19 ‘Cicada’ variant spreads to 25 states – Morning Medical Update

FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions

The FDA approves a new obesity pill, giving patients another option

FDA approves Lilly obesity pill, triggering battle with Novo Nordisk

FDA approves GLP-1 weight loss pill Foundayo from Eli Lilly

FDA Approves Eli Lilly’s GLP-1 Pill

FDA Approves Eli Lilly's Obesity Pill, Foundayo

FDA grants speedy approval to Eli Lilly’s weight-loss pill for obesity